BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Oxford Gene Technology Ltd. Acquires Sense Proteomic Limited To Develop Biomarker Discovery Business


3/17/2009 1:52:31 PM

Oxford, UK, March 17, 2009 - Oxford Gene Technology (OGT) is pleased to announce the acquisition of Sense Proteomic Ltd., a UK-based company engaged in the discovery of disease-specific biomarkers based on its innovative functional protein array technology.

Using its proprietary protein array platform, Sense Proteomic has identified autoantibody signatures with the potential to:

• improve disease diagnosis and prognosis

• identify stage of a disease by monitoring the changes in autoantibody production during disease progression

• monitor the response to therapeutic interventions

• improve clinical outcomes by the stratification of patients for clinical trials and treatment.

Sense Proteomic has identified biomarker panels for several diseases including prostate cancer and systemic lupus erythematosus, and has other biomarker discovery programmes in progress.

Mike Evans, OGT’s CEO, said: “Sense Proteomic’s highly skilled scientific team has already demonstrated significant progress in developing biomarker panels based on its novel functional protein array platform. This deal, combined with our recent development of an ultra high throughput DNA microarray facility, gives OGT a unique blend of genomic and proteomic technologies and will lead to the development of biomarkers with profound clinical significance.”

Rachel Fallon, Sense Proteomic’s joint CEO, said: “This transaction represents a rare opportunity to discover important biomarkers for disease using more than one approach. The biomarkers can be detected using a simple blood test for early diagnosis and prognosis of disease. We look forward to integrating with OGT’s current capabilities and microarray expertise.”

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES